Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens.
The prevalence of genotypic resistance to nucleoside analogues (NA) was examined using a line probe assay (LiPA, Innogenetics, Spain) and a point mutation assay to test for codon 151 polymorphism in plasma from 34 individuals who had been exposed to NA for longer than 1 year. The testing was repeated in the same population after 6 months of being on a new potent protease inhibitor (PI)-containing antiretroviral combination. Only nine (47%) of the 19 patients initially carrying the codon 41 mutation restored zidovudine wild-type (WT) virus population. Similarly, eight (33%) out of 24 carrying the codon 215 mutation restored the wild-type variant. Two subjects carrying codon 74 didanosine mutation reverted to wild-type genotype, as well as two (18%) out of 11 harbouring the codon 184 lamivudine-resistant variant. To conclude, the extent to which drug recycling might be of benefit in subjects showing a restoration of genotypic sensitivity to former drugs needs to be explored.
Pèrez-Olmeda
M
M
Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain.
Rubio
A
A
Puig
T
T
Gômez-Cano
M
M
Ruiz
L
L
Leal
M
M
Clotet
B
B
Soriano
V
V
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003062:Codon; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005838:Genotype; D006678:HIV / Q000145:classification / Q000187:drug effects / Q000235:genetics; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009154:Mutation; D009705:Nucleosides / Q000627:therapeutic use
D019380:Anti-HIV Agents; D003062:Codon; D017320:HIV Protease Inhibitors; D009705:Nucleosides